NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 11:52
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15.18 mln
Float4.08 mln
Earnings Date05/12/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
12.00
Transformational upside
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.05
Debt-free
ROE
-241
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cellectar Biosciences is a US-based clinical-stage company focused entirely on developing cancer treatments. Its most advanced therapy, CLR 131, targets several blood cancers and select solid tumors, and is currently being tested across multiple clinical trials in both adult and pediatric patients. The company is also building a broader pipeline of radioactive drug compounds and maintains research partnerships to expand its treatment options. Founded in 2002 and based in Florham Park, New Jersey, Cellectar is working to bring more precise cancer-fighting therapies from the lab to patients.
